{"id":390227,"date":"2020-05-11T00:00:00","date_gmt":"2020-05-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0003-2020-biopharma-type-2-diabetes-access-and-reimbursement-us-2020\/"},"modified":"2026-05-07T23:22:01","modified_gmt":"2026-05-07T23:22:01","slug":"acremd0003-2020-biopharma-type-2-diabetes-access-and-reimbursement-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acremd0003-2020-biopharma-type-2-diabetes-access-and-reimbursement-us-2020\/","title":{"rendered":"Type 2 Diabetes | Access and Reimbursement | US | 2020"},"content":{"rendered":"<p>The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic therapies, the type 2 diabetes access and reimbursement space is both extremely dynamic and highly influential on treatment patterns. Branded therapies experience high rates of prescribing restrictions as payers steer prescriptions toward less-expensive drug. Manufacturers of agents like the SGLT-2 inhibitors, GLP-1 receptor agonists, and insulins must carefully navigate contract agreements\/rebates with payers to gain favorable formulary coverage.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>On what tiers do payers place leading brands such as Novo Nordisk\u2019s Ozempic and Eli Lilly\u2019s Trulicity, and what restrictions do they impose?<\/li>\n<li>What clinical factors most influence formulary coverage of type 2 diabetes therapies?<\/li>\n<li>What contracting agreements do MCOs report are in place for long-acting insulins such as Sanofi\u2019s Lantus, Novo Nordisk\u2019s Tresiba, and Boehringer Ingelheim \/ Eli Lilly\u2019s Basaglar?<\/li>\n<li>What role do reimbursement restrictions and patient cost play in physicians\u2019 decisions to prescribe therapies such as Johnson &#038; Johnson\u2019s Invokana, AstraZeneca\u2019s Farxiga, and Boehringer Ingelheim \/ Eli Lilly\u2019s Jardiance for type 2 diabetes?<\/li>\n<li>What percentage of MCOs use pharmacoeconomic or health economic models such as cost-utility analysis?<\/li>\n<\/ul>\n<p>Geography: United States<\/p>\n<p>Primary Research: Survey of 140 U.S. endocrinologists and primary care physicians (PCPs). Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs\/MDs).<\/p>\n","protected":false},"template":"","class_list":["post-390227","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390227\/revisions"}],"predecessor-version":[{"id":576522,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390227\/revisions\/576522"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}